ALPS Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-49,166
| Closed | -$1.89M | – | 1161 |
|
|
2023
Q2 | $1.89M | Buy |
49,166
+5,786
| +13% | +$149K | 0.02% | 321 |
|
|
2023
Q1 | $1M | Buy |
43,380
+39
| +0.1% | +$930 | 0.01% | 469 |
|
|
2022
Q4 | $1.14M | Buy |
43,341
+9,033
| +26% | +$200K | 0.01% | 429 |
|
|
2022
Q3 | $674K | Sell |
34,308
-2,200
| -6% | -$44.1K | 0.01% | 546 |
|
|
2022
Q2 | $639K | Sell |
36,508
-17,856
| -33% | -$280K | 0.01% | 541 |
|
|
2022
Q1 | $889K | Sell |
54,364
-6,857
| -11% | -$93.2K | 0.01% | 323 |
|
|
2021
Q4 | $999K | Buy |
61,221
+6,318
| +12% | +$89.9K | 0.01% | 361 |
|
|
2021
Q3 | $701K | Sell |
54,903
-3,858
| -7% | -$50.8K | 0.01% | 445 |
|
|
2021
Q2 | $830K | Sell |
58,761
-17,503
| -23% | -$280K | 0.01% | 426 |
|
|
2021
Q1 | $1.19M | Buy |
76,264
+47,323
| +164% | +$772K | 0.01% | 381 |
|
|
2020
Q4 | $459K | Buy |
28,941
+8,240
| +40% | +$124K | 0.01% | 511 |
|
|
2020
Q3 | $252K | Sell |
20,701
-1,355
| -6% | -$18.2K | ﹤0.01% | 768 |
|
|
2020
Q2 | $255K | Buy |
+22,056
| New | +$304K | ﹤0.01% | 632 |
|
|
2019
Q4 | – | Sell |
-31,960
| Closed | -$169K | – | 867 |
|
|
2019
Q3 | $169K | Sell |
31,960
-1,545
| -5% | -$10.3K | ﹤0.01% | 821 |
|
|
2019
Q2 | $258K | Sell |
33,505
-4,853
| -13% | -$73.9K | ﹤0.01% | 863 |
|
|
2019
Q1 | $763K | Buy |
38,358
+1,656
| +5% | +$28.9K | 0.01% | 393 |
|
|
2018
Q4 | $484K | Buy |
36,702
+8,721
| +31% | +$174K | ﹤0.01% | 489 |
|
|
2018
Q3 | $1.03M | Buy |
27,981
+5,130
| +22% | +$165K | 0.01% | 393 |
|
|
2018
Q2 | $800K | Buy |
22,851
+2,837
| +14% | +$109K | 0.01% | 398 |
|
|
2018
Q1 | $931K | Buy |
20,014
+3,478
| +21% | +$127K | 0.01% | 326 |
|
|
2017
Q4 | $620K | Buy |
16,536
+1,840
| +13% | +$80.3K | ﹤0.01% | 377 |
|
|
2017
Q3 | $783K | Buy |
14,696
+2,075
| +16% | +$123K | 0.01% | 285 |
|
|
2017
Q2 | $719K | Buy |
12,621
+1,062
| +9% | +$53.3K | 0.01% | 285 |
|
|
2017
Q1 | $621K | Sell |
11,559
-1,354
| -10% | -$76.5K | ﹤0.01% | 276 |
|
|
2016
Q4 | $736K | Sell |
12,913
-3,581
| -22% | -$217K | 0.01% | 236 |
|
|
2016
Q3 | $1.02M | Sell |
16,494
-1,659
| -9% | -$117K | 0.01% | 224 |
|
|
2016
Q2 | $1.03M | Buy |
18,153
+3,932
| +28% | +$239K | 0.01% | 206 |
|
|
2016
Q1 | $911K | Sell |
14,221
-2,436
| -15% | -$197K | 0.01% | 190 |
|
|
2015
Q4 | $2.34M | Sell |
16,657
-2,826
| -15% | -$384K | 0.02% | 165 |
|
|
2015
Q3 | $18.9K | Buy |
19,483
+7,778
| +66% | +$926K | 0.02% | 173 |
|
|
2015
Q2 | $1.77M | Buy |
+11,705
| New | +$1.93M | 0.02% | 174 |
|
ALPS Advisors's KDNY Position: Q3 2023 in Review
ALPS Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 49,166 shares — an estimated $1.89M sold.
ALPS Advisors first reported a position in KDNY in Q2 2015 and held it in 31 quarters. The position peaked at $2.34M in Q4 2015. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- ALPS Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- ALPS Advisors sold 49,166 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.89M.
- ALPS Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 31 quarters.
- ALPS Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $2.34M in Q4 2015.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on ALPS Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.